- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06101095
Eine Studie zur Bewertung der Funktion und des Umbaus der Speiseröhre mit Dupilumab im Vergleich zu Placebo über 24 Wochen, gefolgt von einer 104-wöchigen offenen Behandlung bei erwachsenen Teilnehmern mit EoE (Langzeitstudie zur REMOdeling mit Dupilumab bei eosinophiler Ösophagitis)
Eine randomisierte, multizentrische, doppelblinde, parallele, 24-wöchige, placebokontrollierte Phase-4-Studie, gefolgt von einer 104-wöchigen offenen Studie zur Bewertung der Wirksamkeit von Dupilumab auf die Funktion und den Umbau der Speiseröhre bei erwachsenen Teilnehmern mit eosinophiler Ösophagitis (EoE)
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis.
Duration of study period (per participant)
- Screening period: Up to 12 weeks before Week 0
- Randomized double-blind period: 24 weeks
- Open label period: 104 weeks
- Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first.
There will be ten (10) site visits, and five (5) direct-to-participant IMP delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. In this case, IMP will be dispensed at the study site).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The duration per participant will be up to 152 weeks.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
São Paulo, Brasilien, 01323-020
- Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760003
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 41825-010
- Itaigara Memorial - Hospital Dia- Site Number : 0760005
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90610-000
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760006
-
-
São Paulo
-
Campinas, São Paulo, Brasilien, 13010-001
- Clínica Loema - Unidade I- Site Number : 0760007
-
Sorocaba, São Paulo, Brasilien, 18040-425
- Clinica de Alergia Martti Antila- Site Number : 0760001
-
-
-
-
-
Haifa, Israel, 3104802
- Investigational Site Number : 3760006
-
Haifa, Israel, 3109601
- Investigational Site Number : 3760002
-
Jerusalem, Israel, 9103102
- Investigational Site Number : 3760005
-
Jerusalem, Israel, 9112001
- Investigational Site Number : 3760004
-
Tel Aviv, Israel, 6423906
- Investigational Site Number : 3760003
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Investigational Site Number : 1240006
-
Vancouver, British Columbia, Kanada, V6Z 2K5
- Investigational Site Number : 1240004
-
-
Quebec
-
Montreal, Quebec, Kanada, H4A 3T2
- Investigational Site Number : 1240002
-
-
-
-
-
Wetzikon, Schweiz, 8620
- Investigational Site Number : 7560001
-
Zurich, Schweiz, 8091
- Investigational Site Number : 7560002
-
-
-
-
California
-
Murrieta, California, Vereinigte Staaten, 92563
- United Gastroenterologists - Murrieta- Site Number : 8400001
-
San Francisco, California, Vereinigte Staaten, 94143
- University of California San Francisco - Parnassus Heights- Site Number : 8400020
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32256
- Borland Groover Clinic- Site Number : 8400016
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83706
- Treasure Valley Medical Research- Site Number : 8400018
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern University- Site Number : 8400003
-
Glenview, Illinois, Vereinigte Staaten, 60026
- GI Alliance - Glenview- Site Number : 8400012
-
Gurnee, Illinois, Vereinigte Staaten, 60031
- Illinois Gastroenterology Group- Site Number : 8400004
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa- Site Number : 8400006
-
-
Massachusetts
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- University of Massachusetts Chan Medical School- Site Number : 8400019
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic Hospital Rochester- Site Number : 8400008
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27514
- University of North Carolina at Chapel Hill- Site Number : 8400007
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Cleveland Clinic - Cleveland- Site Number : 8400009
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Penn Medicine: University of Pennsylvania Health System- Site Number : 8400010
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77087
- Private Practice - Dr. Martin Yudovich- Site Number : 8400015
-
Mansfield, Texas, Vereinigte Staaten, 76063
- GI Alliance - Mansfield- Site Number : 8400017
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- A documented diagnosis of EoE by endoscopic biopsy.
- Baseline endoscopic biopsies with a demonstration on central reading of intraepithelial eosinophilic infiltration.
- History (by participant report) of an average of at least 2 episodes of dysphagia (with intake of solids) per week in the 4 weeks prior to screening.
- Body weight ≥40 kg.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Other causes of esophageal eosinophilia or the following conditions: hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome).
- Active Helicobacter pylori infection.
- History of achalasia, Crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery.
- Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to10 mm upper endoscope or any critical esophageal stricture that requires dilation at screening.
- History of bleeding disorders or esophageal varices.
- Treatment with swallowed topical corticosteroids within 8 weeks prior to baseline.
- Initiation or change of a food elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to screening.
- Participation in prior dupilumab clinical study or participants currently treated or have been treated with commercially available dupilumab or contraindicated to dupilumab per local labelling.
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
SC injection as per protocol |
SC injection as per protocol |
|
Experimental: Dupilumab
Subcutaneous injection (SC) as per protocol |
Subcutaneous injection (SC) as per protocol |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe (EndoFLIP)
Zeitfenster: From baseline to Week 24
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline to Week 24
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Inzidenz behandlungsbedingter unerwünschter Ereignisse (TEAEs) und schwerwiegender unerwünschter Ereignisse (SAEs)
Zeitfenster: Von der ersten IMP-Verabreichung bis zum Ende der Nachbeobachtungszeit nach der Behandlung (Woche 139)
|
Von der ersten IMP-Verabreichung bis zum Ende der Nachbeobachtungszeit nach der Behandlung (Woche 139)
|
|
|
Inzidenz unerwünschter Ereignisse von besonderem Interesse (AESIs)
Zeitfenster: Von der ersten IMP-Verabreichung bis zum Ende der Nachbeobachtungszeit nach der Behandlung (Woche 139)
|
Von der ersten IMP-Verabreichung bis zum Ende der Nachbeobachtungszeit nach der Behandlung (Woche 139)
|
|
|
Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Zeitfenster: From baseline up to Week 24
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline up to Week 24
|
|
Absolute change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Zeitfenster: From baseline up to Week128
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline up to Week128
|
|
Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Zeitfenster: From Baseline up to Week 128
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From Baseline up to Week 128
|
|
Change from baseline in eosinophilic esophagitis-endoscopic reference score (EoE-EREFS)
Zeitfenster: From baseline up to Week 128
|
EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease. |
From baseline up to Week 128
|
|
Change from baseline in eosinophilic esophagitis (EoE-HSS) Grade
Zeitfenster: From Baseline up to Week 128
|
Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities. |
From Baseline up to Week 128
|
|
Change from baseline in EoE-HSS Stage
Zeitfenster: From Baseline up to Week 128
|
Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities. |
From Baseline up to Week 128
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤6 eosinophils/high power field (Eos/HPF)
Zeitfenster: At Weeks 24, 76 and 128
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Weeks 24, 76 and 128
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤15 Eos/HPF
Zeitfenster: At Week 24
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Week 24
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/HPF
Zeitfenster: At Weeks 24, 76 and 128
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Weeks 24, 76 and 128
|
|
Change from baseline in normalized enrichment score (NES) for EoE diagnostic panel (EDP) transcriptome signature
Zeitfenster: From baseline up to Week 128 (EOT)
|
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease). |
From baseline up to Week 128 (EOT)
|
|
Change from baseline in normalized enrichment score (NES) for type 2 inflammation transcriptome signature
Zeitfenster: From Baseline up to Week 128 (EOT)
|
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease). |
From Baseline up to Week 128 (EOT)
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienleiter: Clinical Sciences & Operations, Sanofi
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Dellon ES, Carlson DA, Greuter T, Collins MH, Lankarani A, Talreja N, Ravi K, Simoes Neto J, Afif W, Gonsalves NP, Lynch KL, Zaghloul S, Cunoosamy D, Durrani SR, Zhang M, Raphael BP, Angello JT, Radwan A, Almansa C, Biedermann L. Dupilumab Improves Esophageal Distensibility in EoE: 24-Week Results From the REMODEL Randomized Trial. Am J Gastroenterol. 2026 Oct 12. doi: 10.14309/ajg.0000000000004227. Online ahead of print.
- Dellon ES, Savarino EV, Zaghloul S, Angello JT, Zhang M, Raphael BP, Radwan A, Bredenoord AJ. Study design of the phase IV, randomized, placebo-controlled REMOdeling with Dupilumab in Eosinophilic esophagitis Long-term (REMODEL) trial. Ther Adv Gastroenterol. 2025 Oct 9;18:17562848251383782. doi: 10.1177/17562848251383782. eCollection 2025.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Immunsystems
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Überempfindlichkeit, sofort
- Überempfindlichkeit
- Eosinophilie
- Leukozytenerkrankungen
- Hämatologische Erkrankungen
- Erkrankungen der Speiseröhre
- Gastroenteritis
- Ösophagitis
- Hämische und lymphatische Krankheiten
- Eosinophile Ösophagitis
- Dupilumab
Andere Studien-ID-Nummern
- LPS17558
- U1111-1280-5266 (Registrierungskennung: ICTRP)
- 2022-502491-23 (Registrierungskennung: CTIS)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .